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1. INTRODUCTION {#jcla23132-sec-0005}
===============

Colorectal cancer (CRC) is one of the common cancers around the world, the morbidity and mortality rates of which ranked third in 2018.[1](#jcla23132-bib-0001){ref-type="ref"} Currently, colorectal cancer is divided into right‐sided colon cancer (RCC) and left‐sided colorectal cancer (LCRC).[2](#jcla23132-bib-0002){ref-type="ref"} Accumulating studies have demonstrated that RCC and LCRC behave differently in terms of genetic expression, embryologic development, epidemiology, clinicopathological characteristics, and even overall survival.[2](#jcla23132-bib-0002){ref-type="ref"}, [3](#jcla23132-bib-0003){ref-type="ref"}, [4](#jcla23132-bib-0004){ref-type="ref"}, [5](#jcla23132-bib-0005){ref-type="ref"} Patients with RCC are more likely to be older and female and have larger, more advanced tumors that are poorly differentiated with microsatellite instability‐high (MSI‐high) and 5'‐C‐phosphate‐G‐3' (CpG) island methylation phenotype‐high (CIMP‐high) phenotypes; these patients typically also have a higher number of BRAF mutations and are more likely to have worse survival outcomes.[5](#jcla23132-bib-0005){ref-type="ref"}, [6](#jcla23132-bib-0006){ref-type="ref"}, [7](#jcla23132-bib-0007){ref-type="ref"} Although differences in oncological outcomes based on tumor sidedness have been reported, it is still controversial. Most studies have reported that RCC patients have worse prognosis compared with LCRC patients.[5](#jcla23132-bib-0005){ref-type="ref"}, [8](#jcla23132-bib-0008){ref-type="ref"}, [9](#jcla23132-bib-0009){ref-type="ref"}, [10](#jcla23132-bib-0010){ref-type="ref"} However, recent studies have found that there is no difference in 5‐year mortality between RCC and LCRC patients.[11](#jcla23132-bib-0011){ref-type="ref"}

An increasing number of studies have shown that inflammation plays a crucial role in the pathogenesis, development, and progression of various cancers, including colorectal cancer.[12](#jcla23132-bib-0012){ref-type="ref"}, [13](#jcla23132-bib-0013){ref-type="ref"}, [14](#jcla23132-bib-0014){ref-type="ref"} Growing evidence has indicated that a systemic inflammatory response negatively correlates with postoperative survival in CRC patients.[15](#jcla23132-bib-0015){ref-type="ref"} The systemic inflammatory state can be represented by the level of a variety of biomarkers, such as neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR), lymphocyte‐to‐monocyte ratio (LMR), C‐reactive protein (CRP), procalcitonin (PCT), and erythrocyte sedimentation rate (ESR). However, CRP, PCT, and ESR are not routinely detected in clinical treatment for CRC. In contrast, NLR, PLR, and LMR are simple and easy to measure, so they are widely used in clinical practice. At the same time, recent research has suggested that NLR, PLR, and LMR may be predictors of overall survival in CRC.[15](#jcla23132-bib-0015){ref-type="ref"}, [16](#jcla23132-bib-0016){ref-type="ref"} Guo et al[17](#jcla23132-bib-0017){ref-type="ref"}reported that different inflammatory factors exhibit different prognostic roles in unresectable RCC and LCRC. However, the differences in inflammatory biomarkers and their prognostic value between stage I‐III RCC and LCRC are unclear. Therefore, in the present study, we aimed to compare oncological outcomes and inflammatory biomarkers between right‐sided and left‐sided stage I‐III CRC after curative resection.

2. MATERIALS AND METHODS {#jcla23132-sec-0006}
========================

2.1. Patients {#jcla23132-sec-0007}
-------------

This study included 339 consecutive patients with primary CRC who underwent radical resection in the Department of Gastrointestinal Surgery, the First Affiliated Hospital of Shantou University Medical College between January 2012 and January 2014. The inclusion criteria for patient enrollment were as follows: (a) Patients histologically confirmed to have colorectal adenocarcinoma; (b) patients diagnosed with stage I to III cancer according to the 8th edition of the American Joint Committee on Cancer (AJCC); and (c) patients with complete clinicopathologic and follow‐up data. The exclusion criteria were as follows: (a) a previous history of malignant diseases; (b) preoperative anti‐cancer treatment; (c) evidence of infectious diseases, blood diseases, tissue diseases, immunological diseases, other gastrointestinal diseases, or other cancers; and (d) emergency surgery due to bowel obstruction or perforation. None of the included patients died of surgical complications. Patients with stage III and high‐risk stage II were generally offered 5‐fluorouracil‐based adjuvant chemotherapy. The adjuvant chemotherapy regimen was as follows: oxaliplatin 85 mg/m^2^ intravenously over 2 hours on day 1, leucovorin 400 mg/m^2^ intravenously over 2 hours on day 1, 5‐ fluorouracil 400 mg/m^2^ intravenously bolus on day 1, and then 1200 mg/m^2^/day for 2 days (total 2400 mg/m^2^ over 46‐48 hours) continuous infusion, repeated every 2 weeks for a total of 24 weeks.

2.2. Definitions {#jcla23132-sec-0008}
----------------

Currently, there is no consensus on the demarcation between RCC and LCRC. Moreover, the distal third of the transverse colon, which is the embryological boundary line, was difficult to determine in retrospective analyses. Therefore, the splenic flexure was used to distinguish RCC and LCRC in most of the available clinical reports.[18](#jcla23132-bib-0018){ref-type="ref"}, [19](#jcla23132-bib-0019){ref-type="ref"}, [20](#jcla23132-bib-0020){ref-type="ref"} In this study, RCC was defined as a tumor localized from the cecum to transverse colon, and LCRC was defined as a tumor localized from the splenic flexure to rectum. All blood tests were performed within one week before surgery, and the counts of neutrophils (N), platelets (P), lymphocytes (L), and monocytes (M) were measured for calculation of the NLR (N/L), PLR (P/L), and LMR (L/M).

Disease‐free survival (DFS) was defined as the time from the date of surgery to the date of the detection of recurrence, death, or last follow‐up. Overall survival (OS) was defined as the time from the date of operation to the date of death or last follow‐up. The latest follow‐up was conducted on January 31, 2019. The protocol was approved by the Ethics Committee of the First Affiliated Hospital of Shantou University Medical College, China.

2.3. Statistical analysis {#jcla23132-sec-0009}
-------------------------

All statistical analyses were performed using SPSS software version 24.0 (SPSS). The Kolmogorov‐Smirnov test was selected to assess the normality of continuous variables. Student\'s *t* test was used for normally distributed parameters, but otherwise the Mann‐Whitney *U* test was performed. Categorical variables were analyzed using the chi‐square test or Fisher exact test. The DFS and OS rates were examined using the Kaplan‐Meier method, and the difference was compared using the log‐rank test. The relation between inflammatory biomarkers and prognosis was analyzed using Cox proportional hazards regression. Variables found to be statistically significant in univariate analysis were further assessed with multivariate Cox models using a forward stepwise method. A *P‐*value \<.05 was considered to be significant.

3. RESULTS {#jcla23132-sec-0010}
==========

3.1. Baseline characteristics {#jcla23132-sec-0011}
-----------------------------

In total, 339 cases were enrolled in the study, including 125 patients with RCC and 214 patients with LCRC. The comparison of baseline characteristics and clinicopathological features according to the tumor location is shown in Table [1](#jcla23132-tbl-0001){ref-type="table"}.

###### 

Clinicopathological characteristics of RCC and LCRC patients

  Characteristics                    RCC (%)               LCRC (%)             *P*‐value
  ---------------------------------- --------------------- -------------------- -----------
  Number of patients                 125                   214                   
  Age (years, mean ± SD)             64.2 ± 11.7           61.4 ± 11.5          .028
  Gender                                                                        
  Male                               67 (53.6%)            131 (61.2%)          .170
  Female                             58 (46.4%)            83 (38.8%)           
  T stage                                                                       
  T1                                 5 (4.0%)              13 (6.1%)            .650
  T2                                 16 (12.8%)            32 (15.0%)           
  T3                                 53 (42.4%)            94 (43.9%)           
  T4                                 51 (40.8%)            75 (35.0%)           
  N stage                                                                       
  N0                                 65 (52.0%)            125 (58.4%)          .032
  N1                                 32 (25.6%)            64 (29.9%)           
  N2                                 28 (22.4%)            25 (11.7%)           
  TNM stage                                                                     
  I                                  11 (8.8%)             34 (15.9%)           .155
  II                                 54 (43.2%)            91 (42.5%)           
  III                                60 (48.0%)            89 (41.6%)           
  Differentiation                                                               
  Poor                               39 (31.2%)            43 (20.1%)           .021
  Well/moderate                      86 (68.8%)            171 (79.9%)          
  Lymphovascular invasion                                                       
  \+                                 65 (52.0%)            87 (40.7%)           .043
  −                                  60 (48.0%)            127 (59.3%)          
  Perineural invasion                                                           
  \+                                 29 (23.2%)            41 (19.2%)           .375
  −                                  96 (73.8%)            173 (80.8%)          
  Number of harvested lymph node                                                
  ≥12                                103 (82.4%)           172 (80.4%)          .646
  \<12                               22 (17.6%)            42 (19.6%)           
  Surgical complications                                                        
  Yes                                19 (15.2%)            27 (12.6)            .503
  No                                 106 (84.8%)           187 (87.4)           
  Adjuvant chemotherapy                                                         
  Yes                                103 (82.4%)           165 (77.1%)          .248
  No                                 22 (17.6%)            49 (22.9%)           
  Recurrence                                                                    
  Local recurrence                   10 (22.7%)            14 (27.4%)           .649
  Metastatic recurrence              29 (65.9%)            31 (60.8%)           
  Both                               5 (11.4%)             6 (11.8%)            
  CEA (median, quartile) (ng/mL)     4.33 (2.28‐9.65)      4.14 (2.05‐8.76)     .643
  NE (median, quartile) (10^9^/L)    4.68 (3.36‐6.82)      4.22 (3.17‐5.60)     .105
  PLT (median, quartile) (10^9^/L)   301 (247‐385)         238 (205‐238)        \<.001
  LY (median, quartile) (10^9^/L)    1.72 (1.30‐2.24)      1.90 (1.48‐2.39)     .016
  MO (median, quartile) (10^9^/L)    0.56 (0.42‐0.68)      0.52 (0.41‐0.65)     .217
  NLR (median, quartile)             2.6 (1.9‐3.9)         2.1 (1.5‐3.4)        .002
  PLR (median, quartile)             185.8 (130.6‐274.3)   127.1 (97.4‐174.4)   \<.001
  LMR (median, quartile)             3.2 (2.3‐4.1)         3.7 (2.7‐4.8)        .002

Abbreviations: CEA, carcinoembryonic antigen; LCRC, left‐sided colorectal cancer; LMR, lymphocyte‐monocyte ratio; LY, lymphocytes; MO, monocytes; NE, neutrophils; NLR, neutrophil‐lymphocyte ratio; PLR, platelet‐lymphocyte ratio; PLT, platelets; RCC, right‐sided colon cancer.
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Patients with RCC were significantly more likely to be older (mean year, 64.2 vs 61.4, *P* = .028). In the distribution of gender, there tended to be more females among patients with RCC (46.4% vs 38.8%, *P* = .170), but this difference was not statistically significant. For TNM stage, N stage was significantly different between the two groups (*P* = .032), but no significant difference was observed in TNM stage (*P* = .155) and T stage (*P* = .650). RCC exhibited more cases of poor differentiation and lymphovascular invasion compared to LCRC (*P* = .021 and*P* = .043, respectively).There were no significant differences in perineural invasion, number of harvested lymph nodes, surgical complications, adjuvant chemotherapy, and the pattern of recurrence between RCC and LCRC. Patients with RCC had increased carcinoembryonic antigen, neutrophils, platelets, and monocytes but decreased lymphocytes. However, only platelets (*P* \< .001) and lymphocytes (*P* = .016) showed significant difference. Compared with LCRC patients, the NLR (*P* = .002) and PLR (*P* \< .001) were significantly elevated, whereas LMR (*P* = .002) was obviously lower in RCC patients.

3.2. Oncological outcomes and inflammatory markers {#jcla23132-sec-0012}
--------------------------------------------------

In the survival analyses (Figure [1](#jcla23132-fig-0001){ref-type="fig"}A,D) with a median follow‐up of 54 months, RCC patients had poorer OS and DFS rates compared with LCRC patients in stage I‐III (61.6% vs 71.5%, *P* = .018; 64.8% vs 76.2%, *P* = .006). In the subgroup analyses (Figure [1](#jcla23132-fig-0001){ref-type="fig"}B,E), no significant differences of OS and DFS were observed according to the tumor location at stage II (68.5% vs 71.4%, *P* = .589; 70.4% vs 74.7%, *P* = .464). For Stage III (Figure [1](#jcla23132-fig-0001){ref-type="fig"}C,F), however, patients with RCC had significantly worse OS and DFS compared to LCRC patients (51.7% vs 64.0%, *P* = .045; 55.0% vs 68.5%, *P* = .021).The median patient age, CEA, NLR, PLR, and LMR were 64 years, 4.25 ng/mL, 2.3, 145.2, and 3.5, respectively, and these values were used as cutoffs. Based on these cutoff values, both RCC and LCRC patients were divided into the following two groups for further analysis: high NLR (≥2.3) and low NLR (\<2.3); high PLR (≥145.2) and low PLR (\<145.2); and high LMR (≥3.5) and low LMR (\<3.5).The association between survival and inflammatory markers was analyzed using Kaplan‐Meier analysis. In RCC (Figure [2](#jcla23132-fig-0002){ref-type="fig"}), patients with high NLR (*P* = .015; *P* = .025), high PLR (*P* = .011; *P* = .021), and low LMR (*P* = .018; *P* = .012) had significantly poorer OS and DFS than those with low NLR, low PLR, and high LMR. For patients with LCRC (Figure [3](#jcla23132-fig-0003){ref-type="fig"}), high NLR (*P* = .013) and PLR (*P* = .004) correlated with significantly shorter OS compared with low NLR and PLR, but no significant correlation was observed between LMR (*P* = .099) and OS. Similar results were observed between inflammatory markers and DFS (NLR, *P* = .009; PLR, *P* = .003; LMR, *P* = .101).

![Overall survival and disease‐free survival for patients with RCC vs LCRC after curative surgery. (A, D) Stages I‐III. (B, E) Stage II. (C, F) Stage III. RCC, right‐sided colon cancer; LCRC, left‐sided colorectal cancer](JCLA-34-e23132-g001){#jcla23132-fig-0001}

![Kaplan‐Meier curves of overall survival (A, B, C) and disease‐free survival (D, E, F) for right‐sided colon cancer patients based on different levels of NLR, PLR, and LMR. NLR, neutrophil‐lymphocyte ratio; PLR, platelet‐lymphocyte ratio; LMR, lymphocyte‐monocyte ratio](JCLA-34-e23132-g002){#jcla23132-fig-0002}

![Kaplan‐Meier curves of overall survival (A, B, C) and disease‐free survival (D, E, F) for left‐sided colorectal cancer patients based on different levels of NLR, PLR, and LMR. NLR, neutrophil‐lymphocyte ratio; PLR, platelet‐lymphocyte ratio; LMR, lymphocyte‐monocyte ratio](JCLA-34-e23132-g003){#jcla23132-fig-0003}

3.3. Prognostic value of inflammatory biomarkers {#jcla23132-sec-0013}
------------------------------------------------

In the univariate and multivariate Cox regression analyses, NLR, PLR, LMR, N1‐2 stage, CEA, lymphovascular invasion, and poor differentiation were independent prognostic factors for OS in RCC (Table [2](#jcla23132-tbl-0002){ref-type="table"}). For LCRC, PLR, T3‐4 stage, N1‐2 stage, CEA, and poor differentiation were significantly associated with worse OS (Table [2](#jcla23132-tbl-0002){ref-type="table"}).As shown in Table [3](#jcla23132-tbl-0003){ref-type="table"}, NLR, PLR, LMR, N1‐2 stage, CEA, lymphovascular invasion, and poor differentiation were independent prognostic factors for DFS in RCC, whereas the independent predictors for DFS were T3‐4 stage, N1‐2 stage, poor differentiation, lymphovascular invasion, CEA, and PLR in LCRC.

###### 

Univariate and multivariate analyses for prognostic factors of OS after curative resection for stage I‐III RCC and LCRC

  Factors                            Univariate analysis   Multivariate analysis                               
  ---------------------------------- --------------------- ----------------------- -------- ------ ----------- --------
  RCC                                                                                                          
  Age (≥64 vs \<64 y)                1.23                  0.69‐2.17               .480                         
  Gender (male vs female)            1.46                  0.82‐2.61               .197                         
  T stage (T3‐4 vs T1‐2)             2.85                  1.02‐7.94               .045     1.61   0.55‐4.67   .382
  N stage (N1‐2 vs N0)               2.17                  1.22‐3.89               .009     1.98   1.09‐3.60   .024
  Differentiation (poor vs others)   2.21                  1.25‐3.91               .007     1.93   1.07‐3.48   .029
  Lymphovascular invasion            2.53                  1.39‐4.58               .002     2.13   1.13‐4.02   .020
  Perineural invasion                1.84                  0.95‐3.55               .070                         
  No. of lymph node (≥12 vs \<12)    1.16                  0.56‐2.39               .693                         
  CEA(≥4.25 ng/mL vs \<4.25 ng/mL)   1.95                  1.09‐3.49               .024     1.99   1.07‐3.70   .030
  NLR (≥2.3 vs \<2.3)                2.21                  1.15‐4.25               .018     2.54   1.29‐4.98   .007
  PLR (≥145.2 vs \< 145.2)           2.41                  1.20‐4.85               .013     2.73   1.28‐5.83   .010
  LMR (\<3.5 vs ≥3.5)                2.06                  1.12‐3.79               .020     2.08   1.11‐3.89   .022
  LCRC                                                                                                         
  Age (≥64 vs \<64 y)                1.42                  0.86‐2.35               .172                         
  Gender (male vs female)            1.30                  0.77‐2.20               .334                         
  T stage (T3‐4 vs T1‐2)             3.30                  1.42‐7.67               .006     3.39   1.43‐8.04   .005
  N stage (N1‐2 vs N0)               1.98                  1.20‐3.28               .008     1.94   1.17‐3.23   .011
  Differentiation (poor vs others)   2.48                  1.45‐4.24               .001     1.66   0.94‐2.92   .082
  Lymphovascular invasion            3.57                  2.12‐6.03               \<.001   4.04   2.31‐7.06   \<.001
  Perineural invasion                1.54                  0.86‐2.76               .146                         
  No. of lymph node (≥12 vs \<12)    1.60                  0.89‐2.87               .117                         
  CEA(≥4.25 ng/mL vs \<4.25 ng/mL)   2.01                  1.20‐3.36               .008     2.59   1.51‐4.45   .001
  NLR (≥2.3 vs \<2.3)                1.88                  1.13‐3.11               .015     1.51   0.89‐2.55   .125
  PLR (≥145.2 vs \<145.2)            2.05                  1.24‐3.39               .005     2.69   1.57‐4.62   \<.001
  LMR (\<3.5 vs ≥3.5)                1.52                  0.92‐2.52               .101                         

Abbreviations: 95%CI, 95% confidential interval; CEA, carcinoembryonic antigen; HR, hazard ratio; LMR, lymphocyte‐monocyte ratio; NLR, neutrophil‐lymphocyte ratio; OS, overall survival; PLR, platelet‐lymphocyte ratio; RCRC, right‐sided colon cancer.
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###### 

Univariate and multivariate analyses for prognostic factors of DFS after curative resection for stage I‐III RCC and LCRC

  Factors                            Univariate analysis   Multivariate analysis                                
  ---------------------------------- --------------------- ----------------------- -------- ------ ------------ --------
  RCC                                                                                                            
  Age (≥64 vs \<64 y)                1.36                  0.75‐2.48               .315                          
  Gender (male vs female)            1.21                  0.66‐2.19               .540                          
  T stage (T3‐4 vs T1‐2)             3.48                  1.08‐11.25              .037     2.07   0.62‐6.88    .235
  N stage (N1‐2 vs N0)               2.16                  1.17‐3.96               .013     1.98   1.09‐3.60    .036
  Differentiation (poor vs others)   2.31                  1.27‐4.18               .006     2.02   1.10‐3.72    .024
  Lymphovascular invasion            2.51                  1.34‐4.69               .004     2.09   1.07‐4.10    .031
  Perineural invasion                1.63                  0.82‐3.23               .163                          
  No. of lymph node (≥12 vs \<12)    1.33                  0.59‐2.98               .495                          
  CEA(≥4.25 ng/mL vs \<4.25 ng/mL)   2.07                  1.12‐3.83               .021     1.95   1.02‐3.72    .044
  NLR (≥2.3 vs \<2.3)                2.14                  1.08‐4.24               .029     2.32   1.15‐4.66    .018
  PLR (≥145.2 vs \<145.2)            2.31                  1.11‐4.81               .025     2.43   1.09‐5.42    .030
  LMR (\<3.5 vs ≥3.5)                2.25                  1.18‐4.31               .014     2.16   1.11‐4.20    .024
  LCRC                                                                                                           
  Age (≥64 vs \<64 y)                1.47                  0.85‐2.55               .171                          
  Gender (male vs female)            1.49                  0.82‐2.69               .187                          
  T stage (T3‐4 vs T1‐2)             5.42                  1.69‐17.40              .005     5.16   1.58‐16.82   .007
  N stage (N1‐2 vs N0)               1.96                  1.13‐3.41               .017     1.85   1.06‐3.23    .031
  Differentiation (poor vs others)   2.94                  1.67‐5.20               \<.001   1.96   1.07‐3.60    .030
  Lymphovascular invasion            3.34                  1.89‐5.91               \<.001   3.54   1.92‐6.52    \<.001
  Perineural invasion                1.37                  0.72‐2.62               .343                          
  No. of lymph node (≥12 vs \<12)    1.40                  0.73‐2.68               .310                          
  CEA(≥4.25 ng/mL vs \<4.25 ng/mL)   1.90                  1.08‐3.34               .025     2.45   1.35‐4.45    .003
  NLR (≥2.3 vs \<2.3)                2.08                  1.19‐3.63               .010     1.60   0.89‐2.87    .115
  PLR (≥145.2 vs \<145.2)            2.28                  1.31‐3.97               .004     2.84   1.57‐5.15    .001
  LMR (\<3.5 vs ≥3.5)                1.58                  0.91‐2.74               .104                          

Abbreviations: 95%CI, 95% confidential interval; CEA, carcinoembryonic antigen; DFS, disease‐free survival; HR, hazard ratio; LMR, lymphocyte‐monocyte ratio; NLR, neutrophil‐lymphocyte ratio; PLR, platelet‐lymphocyte ratio; RCRC, right‐sided colon cancer.
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4. DISCUSSION {#jcla23132-sec-0014}
=============

In recent years, more and more studies have been performed to distinguish the differences between right‐sided and left‐sided colorectal cancer. Given the markedly different biological and clinical characteristics, RCC and LCRC are considered as two different disease entities.[21](#jcla23132-bib-0021){ref-type="ref"}, [22](#jcla23132-bib-0022){ref-type="ref"} Several publications have reported that older age, females, advanced T stage, node‐positive stage, larger tumor size, and poorer differentiation are more commonly observed for RCC.[4](#jcla23132-bib-0004){ref-type="ref"}, [5](#jcla23132-bib-0005){ref-type="ref"}, [6](#jcla23132-bib-0006){ref-type="ref"}

In this study, we found that patients with RCC are older and have tumors with poorer histological grade and more advanced N stage, which was in concordance with the abovementioned studies. For patients with stage I‐III, we found that RCC patients had poorer prognosis compared to LCRC patients. In stage III, survival was significantly worse in RCC compared with that in LCRC, whereas no significant difference of prognosis was found between the two groups in stages I and II. Our results were in agreement with those reported by Meguid et al,[23](#jcla23132-bib-0023){ref-type="ref"} who identified patients who underwent surgical resection from the SEER database between 1988 and 2003 and found that RCC has poorer prognosis than LCRC. Similarly, Huang et al[18](#jcla23132-bib-0018){ref-type="ref"} analyzed 1198 consecutive colorectal patients, who received surgical treatment from 2002 to 2008, and they reported significantly poorer OS in stage III patients with right‐sided CRC vs those with left‐sided CRC.

The reason for the difference of oncological outcomes between right‐sided and left‐sided CRC is still unclear. Most studies believe that the differences in embryonic origin, genotypes, and phenotypes play a part.[5](#jcla23132-bib-0005){ref-type="ref"}, [18](#jcla23132-bib-0018){ref-type="ref"}, [24](#jcla23132-bib-0024){ref-type="ref"} The right colon is developed from the midgut, which consists of the cecum, ascending colon, and proximal two‐thirds of the transverse colon. In contrast, the left‐sided colorectum is developed from the hindgut, which is composed of the distal third of the transverse colon, the descending colon, the sigmoid colon, and the upper two‐thirds of the anorectal canal. The right‐sided colon and left‐sided colorectum are mainly supplied by the superior and inferior mesenteric arteries, respectively. Physiologically, the right‐sided colon plays a role of absorbing water, while the left‐sided colorectum assists defecation by peristalsis. Based on the above differences of anatomy and physiology, the range of resection for right hemicolectomy is wider than that for left hemicolectomy or anterior resection, causing more damage to the function of the large intestine, which may lead to worse survival in RCC patients after operation. Narayanan et al[25](#jcla23132-bib-0025){ref-type="ref"} found that higher rates of MSI and mutated KRAS oncogenes may contribute to poorer OS of RCC compared to LCRC patients. Eklof et al[26](#jcla23132-bib-0026){ref-type="ref"} also found that RCC with an increase in BRAF mutations exhibits poor prognosis. Moreover, RCC usually presents with advanced stage, increased tumor size, poorer differentiation, and more node positivity than LCRC, which are related to inferior survival.[27](#jcla23132-bib-0027){ref-type="ref"}

Interestingly, we found that the level of inflammatory markers was significantly different between the two groups. Patients with right‐sided cancer had significantly higher NLR and PLR but lower level of LMR compared to patients with left‐sided cancer. Although Yang et al[28](#jcla23132-bib-0028){ref-type="ref"} investigated different expression levels of NLR and PLR between RCC and LCRC, they did not explore the level of LMR. In addition, these researchers found that more LCRC patients express high levels of NLR and PLR, which was inconsistent with our results. However, these researchers did not report whether the different expression is significant. Therefore, more studies with larger sample size are needed to clarify the contradictory results.

The significant difference in inflammatory markers analyzed as independent prognostic factors was the more interesting finding of our study. In RCC, NLR, PLR, and LMR were associated with significantly poorer overall survival and disease‐free survival in univariate and multivariate analyses. However, only PLR was found to be an independent predictor of worse outcome in LCRC. Although many studies have reported that inflammatory markers, such as NLR, PLR, and LMR predict prognosis of patients with CRC,[15](#jcla23132-bib-0015){ref-type="ref"}, [16](#jcla23132-bib-0016){ref-type="ref"} no one has reported the different prognostic values of these parameters according to tumor location in stage I‐III CRC. Corrado et al[15](#jcla23132-bib-0015){ref-type="ref"} analyzed 603 R0 resected CRC patients and found that both NLR and PLR are independent predictors of 5‐year OS. Joseph et al [16](#jcla23132-bib-0016){ref-type="ref"} concluded that LMR is a superior prognostic predictor of OS in patients with CRC undergoing curative resection.

Cancer‐related inflammation is an essential process in malignant tumor growth and can enhance cancer cell invasion, proliferation, metastasis, and immune escape.[29](#jcla23132-bib-0029){ref-type="ref"} Inflammatory cells may produce growth factors for tumor cells, and the tumor microenvironment, in turn, may provide factors that suppress antitumor immune responses.[30](#jcla23132-bib-0030){ref-type="ref"} Neutrophils not only promote tumor cell invasion, proliferation, metastasis, and angiogenesis but also help cancer cells escape from immune surveillance by secreting reactive oxygen species, proteases, vascular endothelial growth factors, and hepatocyte growth factors.[31](#jcla23132-bib-0031){ref-type="ref"}, [32](#jcla23132-bib-0032){ref-type="ref"} Tumor‐associated neutrophils have been observed to promote lung or liver metastasis in CRC.[33](#jcla23132-bib-0033){ref-type="ref"}, [34](#jcla23132-bib-0034){ref-type="ref"} Platelets are remarkably activated in cancer patients and contain a plethora of growth and angiogenic factors that all contribute to tumor growth and angiogenesis.[35](#jcla23132-bib-0035){ref-type="ref"} Furthermore, platelets protect circulating tumor cells from natural killer cell‐mediated lysis by encasing them in a thrombus.[36](#jcla23132-bib-0036){ref-type="ref"} Lymphocytes play a key role in cytotoxic cell death and inhibit proliferation and migration of tumor cells.[37](#jcla23132-bib-0037){ref-type="ref"} A decreased number of lymphocytes are indicative of immune surveillance suppression and ineffectiveness of tumor control, which has been reportedly associated with poor prognosis in CRC patients.[38](#jcla23132-bib-0038){ref-type="ref"} It has also been reported that tumor‐infiltrating lymphocytes (TILs) correlate with peripheral blood lymphocytes.[39](#jcla23132-bib-0039){ref-type="ref"} TILs are more often observed in advanced CRC where tumors display higher programmed death‐ligand 1 (PD‐L1) expression and a significant correlation with worse OS.[40](#jcla23132-bib-0040){ref-type="ref"} Circulating monocytes can improve tumor growth and reduce host immunosurveillance.[41](#jcla23132-bib-0041){ref-type="ref"} Peripheral monocytes migrate into tumor tissue and differentiate into M2 macrophages, promoting immunosuppression, tumor angiogenesis, and metastasis.[42](#jcla23132-bib-0042){ref-type="ref"} Moreover, circulating monocytes have been found to upregulate PD‐L1 expression to inhibit antitumor T‐cell responses.[43](#jcla23132-bib-0043){ref-type="ref"} Considering these reasons, elevated NLR and PLR as well as decreased LMR may contribute to poorer survival in RCC patients.

Although increasing evidence has shown that cancer‐related inflammation has a negative impact on survival,[30](#jcla23132-bib-0030){ref-type="ref"}, [44](#jcla23132-bib-0044){ref-type="ref"} the mechanism for the significant difference in inflammatory markers between RCC and LCRC is still unknown. Anatomically, the right‐sided colon is connected to the ileum, which contains many lymphoid follicles, and the right‐sided colon mesentery may contain a more complex lymphatic system, which may more easily cause a cancer‐related inflammatory and immune response in RCC. Epidemiologically, our results demonstrated that RCC more frequently involves older people. Older patients may be more likely to have uncontrolled systemic inflammation as well as have inferior immune function. With respect to intestinal flora, invasive bacterial biofilms have been associated with increased interleukin‐6 (IL‐6), which was found in 89% of RCC but in only 12% of LCRC.[45](#jcla23132-bib-0045){ref-type="ref"} IL‐6 is a pro‐inflammatory factor and is considered as one of the most important cytokines during tumorigenesis and metastasis.[46](#jcla23132-bib-0046){ref-type="ref"} With regard to molecular mechanisms, phosphoinositide 3‐kinase pathway mutations, which regulate several key events in the inflammatory and immune response,[47](#jcla23132-bib-0047){ref-type="ref"} are significantly associated with proximal CRC.[48](#jcla23132-bib-0048){ref-type="ref"} We propose that greater vascular invasion, more advanced tumor stage, and less differentiation of RCC tumors, such as mucinous and signet‐ring cell adenocarcinoma, result in more intense inflammatory reactions. Neutrophilia, thrombocythemia, lymphopenia, and monocytosis suggest an elevated inflammatory status and decreased immune system response, which contribute to poorer prognosis in RCC patients.

In the present study, we found that the survival and inflammatory markers significantly differed between RCC and LCRC, implying that one of the potential mechanisms for different prognoses is different systemic inflammation. Our study was the first to investigate the different prognostic value of inflammatory biomarkers for RCC and LCRC, suggesting that exploring the difference of inflammatory mechanism may be helpful for tailored treatment for CRC according to tumor location. Therefore, further research on the inflammatory mechanism contributing to the prognosis of CRC is needed for identifying key targets, which will improve the oncological outcomes of RCC and LCRC.

This study had several limitations. First, this was a retrospective and single‐center study with small sample size. Thus, multicenter studies with larger sample size should be performed to validate these results. Second, we did not examine other preoperative inflammatory markers, such as CRP. Hence, the difference in other inflammatory biomarkers between RCC and LCRC is unclear. Third, we did not detect the microsatellite instability status of the included patients, which may result in different expression of inflammatory markers. Fourth, only patients who received curative surgery were enrolled, making the results of this study not applicable to patients with stage IV. Fifth, some baseline variables related to surgical risk, such as physiological and operative scores for the enumeration of mortality and morbidity as well as American Society of Anesthesiologists Physical Status and Charlson Comorbidity Index, were not included.

In conclusion, for stage I‐III CRC, RCC patients had poorer OS and DFS compared with LCRC patients. In stage III, worse OS and DFS were significantly observed in RCC patients. Different inflammatory markers showed different levels and prognostic values in RCC and LCRC. RCC and LCRC should be regarded as two heterogeneous entities. Novel therapeutic strategies are needed, and proper prognostic predictors should be selected according to colorectal tumor location.
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